MERCK NEW PRODUCT NEWS FLOW BUOYS STOCK IN SECOND QUARTER; FIVE NDA APPROVALS, TWO LAUNCHES, PHASE III DATA ON FOSAMAX PROPEL COMPANY TO 15% GAIN
Executive Summary
Merck is regaining its status as Wall Street's favorite pharmaceutical stock on the strength of a quintet of NDA approvals during the second quarter.